Type II variation [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2018-06-22 15:12 (986 d 03:24 ago) – Posting: # 18948
Views: 6,041

Hi Beholder,

» […] whether we need to perform BEQ study in case of changes in amount of tablets in production batch or not? I refer to the table B.II.b.4 Change in the batch size (including batch size ranges) of the finished product

Yes because that’s a Type II (i.e., a major) variation. Only if the conditions for a bio­waiver are applicable you could get around an in vivo study.

Dif-tor heh smusma 🖖
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

Activity
 Admin contact
21,363 posts in 4,462 threads, 1,492 registered users;
online 8 (0 registered, 8 guests [including 8 identified bots]).
Forum time: Thursday 17:37 CET (Europe/Vienna)

Being really good at C++ is like being really good
at using rocks to sharpen sticks.    Thant Tessman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5